Long-term effects of biodegradable versus durable polymercoated sirolimus-eluting stents on coronary arterial wall morphology assessed by virtual histology intravascular ultrasound

Chinese Medical Journal

Volumn 124, Issue 6, 2011, Pages 836-844

  Liu, Hui Liang ^a   Jin, Zhi Geng ^a   Luo, Jian Ping ^a   Ma, Dong Xing ^a   Yang, Sheng Li ^a   Liu, Ying ^a   Han, Wei ^a   Jing, Li Min ^a   Meng, Rong Ying ^a   Zhang, Jiao ^a  

^a GENERAL HOSPITAL OF CHINESE PEOPLE'S ARMED POLICE FORCES   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACETYLSALICYLIC ACID; ATORVASTATIN; CLOPIDOGREL; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; POLYMER; RAPAMYCIN;

ACUTE HEART INFARCTION; ADULT; AGED; ANGIOCARDIOGRAPHY; ARTERY WALL; ARTICLE; BIOCOMPATIBILITY; BIODEGRADABILITY; CLINICAL ARTICLE; CONTROLLED STUDY; CORONARY ARTERY; DRUG COATING; DRUG ELUTING STENT; FEMALE; FOLLOW UP; HISTOLOGY; HUMAN; INCIDENCE; INTRAVASCULAR ULTRASOUND; MALE; MORPHOLOGY; MORPHOMETRICS; OUTCOME ASSESSMENT; PERCUTANEOUS CORONARY INTERVENTION; STABLE ANGINA PECTORIS; UNSTABLE ANGINA PECTORIS;

CORONARY ANGIOGRAPHY; CORONARY ARTERY DISEASE; CORONARY VESSELS; DRUG-ELUTING STENTS; FEMALE; HUMANS; MALE; MIDDLE AGED; SIROLIMUS;

EID: 79952835790     PISSN: 03666999     EISSN: None     Source Type: Journal    
DOI: 10.3760/cma.j.issn.0366-6999.2011.06.007     Document Type: Article

References (32)

1. Moses JW, Leon MB, Popma JJ, Fitzgerald PJ, Holmes DR, O'Shaughnessy C, et al. SIRIUS Investigators. Sirolimuseluting stents versus standard stents in patients with stenosis in a native coronary artery. N Engl J Med 2003; 349: 1315-1323.
2. Stone GW, Ellis SG, Cox DA, Hermiller J, O'Shaughnessy C, Mann JT, et al. One-year clinical results with the slow-release, polymer-based, paclitaxel-eluting TAXUS stent: the TAXUSIV trial. Circulation 2004; 109: 1942-1947.
3. Liistro F, Colombo A. Late acute thrombosis after paclitaxel eluting stent implantation. Heart 2001; 86: 262-264.
4. McFadden EP, Stabile E, Regar E, Cheneau E, Ong AT, Kinnaird T, et al. Late thrombosis in drug-eluting coronary stents after discontinuation of antiplatelet therapy. Lancet 2004; 364: 1519-1521.
5. Ong AT, McFadden EP, Regar E, de Jaegere PP, van Domburg RT, Serruys PW. Late angiographic stent thrombosis (LAST) events with drug-eluting stents. J Am Coll Cardiol 2005; 45: 2088-2092.
6. Takahashi S, Kaneda H, Tanaka S, Miyashita Y, Shiono T, Taketani Y, et al. Late angiographic stent thrombosis after sirolimus-eluting stent implantation. Circ J 2007; 71: 226-228.
7. Virmani R, Guagliumi G, Farb A, Musumeci G, Grieco N, Motta T, et al. Localized hypersensitivity and late coronary thrombosis secondary to a sirolimus-eluting stent: should we be cautious? Circulation 2004; 109: 701-705.
8. Joner M, Finn AV, Farb A, Mont EK, Kolodgie FD, Ladich E, et al. Pathology of drug-eluting stent in humans: delayed healing and thrombotic risk. J Am Coll Cardiol 2006; 48: 193-202.
9. Ge J, Qian J, Wang X, Wang Q, Yan W, Yan Y, et al. Effectiveness and safety of the sirolimus-eluting stents coated with bioabsorbable polymer coating in human coronary arteries. Catheter Cardiovasc Interv 2007; 69: 198-202.
10. Han Y, Jing Q, Chen X, Wang S, Ma Y, Liu H, et al. Long-term clinical, angiographic, and intravascular ultrasound outcomes of biodegradable polymer-coated sirolimus-eluting stents. Catheter Cardiovasc Interv 2008; 72: 177-183.
11. Nasu K, Tsuchikane E, Katoh O, Vince DG, Virmani R, Surmely JF, et al. Accuracy of in vivo coronary plaque morphology assessment: a validation study of in vivo virtual histology compared with in vitro histopathology. J Am Coll Cardiol 2006; 47: 2405-2412.
12. Nair A, Margolis MP, Kuban BD, Vince DG. Automated coronary plaque characterisation with intravascular ultrasound backscatter: ex vivo validation. EuroIntervention 2007; 3: 113-120.
13. Kubo T, Maehara A, Mintz GS, Garcia-Garcia HM, Serruys PW, Suzuki T, et al. Analysis of the long-term effects of drug-eluting stents on coronary arterial wall morphology as assessed by virtual histology intravascular ultrasound. AmHeart J 2010; 159: 271-277.
14. Kim SK, Mintz GS, Hong YJ, Pakala R, Park KS, Pichard AD, et al. The virtual histology intravascular ultrasound appearance of newly placed drug-eluting stents. Am J Cardiol 2008; 102: 1182-1186.
15. Hong MK, Lee CW, Kim YH, Park DW, Lee SW, Park CB, et al. Usefulness of follow-up low-density lipoprotein cholesterol level as an independent predictor of changes of coronary atherosclerotic plaque size as determined by intravascular ultrasound analysis after statin (atorvastatin or simvastatin) therapy. Am J Cardiol 2006; 98: 866-870.
16. Serruys PW, Degertekin M, Tanabe K, Abizaid A, Sousa JE, Colombo A, et al. Intravascular ultrasound findings in the multicenter, randomized, double-blind RAVEL (Randomized study with the sirolimus-eluting velocity balloon-expandable stent in the treatment of patients with de novo native coronary artery lesions) trial. Circulation 2002; 106: 798-803.
17. Sales FJ, Falcão BA, Falcão JL, Ribeiro EE, Perin MA, Horta PE, et al. Evaluation of plaque composition by intravascular ultrasound "virtual histology": the impact of dense calcium on the measurement of necrotic tissue. EuroIntervention 2010; 6: 394-399.
18. Tanigawa J, Barlis P, Dimopoulos K, Dalby M, Moore P, Di Mario C. The influence of strut thickness and cell design on immediate apposition of drug-eluting stents assessed by optical coherence tomography. Int J Cardial 2009; 134: 180-188.
19. Kim SW, Mintz G, Lee WS, Lim SH, Kim GH, Lee KJ, et al. The impact of necrotic core in thin-capped fibroatheroma on post-drug-eluting stent implantation: a virtual histology intravascular ultrasound analysis. Am J Cardiol 2009; 9 suppl 1: 70B.
20. Hong YJ, Jeong MH, Choi YH, Ma EH, Ko JS, Lee MG, et al. Impact of baseline plaque components on plaque progression in nonintervened coronary segments in patients with angina pectoris on rosuvastatin 10 mg/d. Am J Cardiol 2010; 106: 1241-1247.
21. Nasu K, Tsuchikane E, Katoh O, Tanaka N, Kimura M, Ehara M, et al. Effect of fluvastatin on progression of coronary atherosclerotic plaque evaluated by virtual histology intravascular ultrasound. JACC Cardiovasc Interv 2009; 2: 689-696.
22. Perin EC. Choosing a drug-eluting stent: a comparison between Cypher and Taxus. Rev Cardiovasc Med 2005; 6 suppl 1: S13-S21.
23. Gao RL, Xu B, Lu SZ, Chen JL, Han YL, Chen JZ, et al. Safety and efficacy of the CYPHER select sirolimus-eluting stent in the "real world"-clinical and angiographic results from the China CYPHER select registry. Int J Cardial 2008; 125: 339-346.
24. Windecker S, Serruys PW, Wandel S, Buszman P, Trznadel S, Linke A, et al. Biolimus-eluting stent with biodegradable polymer versus sirolimus-eluting stent with durable polymer for coronary revascularisation (LEADERS): a randomized non-inferiority trial. Lancet 2008; 372: 1163-173.
25. Nair A, Kuban BD, Tuzcu EM, Schoenhagen P, Nissen SE, Vince DG. Coronary plaque classification with intravascular ultrasound radiofrequency data analysis. Circulation 2002; 106: 2200-2206.
26. Yao ZH, Matsubara T, Inada T, Suzuki Y, Suzuki T. Neointimal coverage of sirolimus-eluting stents 6 months and 12 months after implantation: evaluation by optical coherence tomography. Chin Med J 2008; 121: 503-507.
27. Burke AP, Farb A, Malcom GT, Liang YH, Smialek J, Virmani R, et al. Coronary risk factors and plaque morphology in men with coronary disease who died suddenly. N Engl J Med 1997; 336: 1276-1282.
28. Rodriguez-Granillo GA, García-García HM, Mc Fadden EP, Valgimigli M, Aoki J, de Feyter P, et al. In vivo intravascular ultrasound-derived thin-cap fibroatheroma detection using ultrasound radiofrequency data analysis. J Am Coll Cardiol 2005; 46: 2038-2042.
29. Liu HB, Xu B, Yang YJ, Wang Y, Qin XW, Yao M, et al. Long-term clinical outcomes after bioabsorbable polymer- and durable polymer-based sirolimus-eluting stents implantation: two-year follow-up results from a large single-center database. Chin Med J 2009; 122: 681-686.
30. Han Y, Jing Q, Xu B, Yang L, Liu H, Shang X, et al. Safety and efficacy of biodegradable polymer-coated sirolimuseluting stents in "real-world" practice: 18-month clinical and 9-month angiographic outcomes. JACC Cardiolvasc Interv 2009; 2: 303-309.
31. Urban P, Gershlick AH, Guagliumi G, Guyon P, Lotan C, Schofer J, et al. Safety of coronary sirolimus-eluting stents in daily clinical practice one-year follow-up of the e-Cypher registry. Circulation 2006; 113: 1434-1441.
32. Stone GW, Maehara A, Lansky AJ, Bruyne BD, Cristea E, Mintz GS, et al. A prospective natural-history study of coronary atherosclerosis. N Engl J Med 2011; 364: 226-235.